BetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.087 USD | -8.03% | -0.34% | +81.25% |
May. 14 | BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 | CI |
May. 03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+81.25% | 10.1M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies